Yazarlar : Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA.

Yayın : Blood

Yayın Yılı : 2010

Pubmed Linki : Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA.

Konu : Lösemi Transfüzyon

Literatür İçeriği :

Abstract

Several cancer treatments are shifting from traditional, time-limited, non-specific cytotoxic chemotherapy cycles to continuous oral treatment with specific protein targeted therapies. In this line, imatinib mesylate, a selective tyrosine kinases inhibitor (TKI), has excellent efficacy in the treatment of chronic myeloid leukemia (CML). It has opened the way to the development of additional anti-CML TKIs, including nilotinib and dasatinib. TKIs are prescribed for prolonged periods, often in patients with comorbidities. Therefore they are regularly co-administered along with treatments at risk of drug-drug interactions. This aspect has been partially addressed so far, calling for a comprehensive review of the published data. We review here the available evidence and pharmacological mechanisms of interactions between imatinib, dasatinib and nilotinib, and widely prescribed co-medications, including known inhibitors or inducers of cytochromes P450 or drug transporters. Information is mostly available for imatinib, well introduced in clinical practice. Several pharmacokinetic aspects yet remain insufficiently investigated for these drugs. Regular updates will be mandatory, and so is the prospective reporting of unexpected clinical observations.

Literatür Arşivi